Benefits of dual COMPASS regimen also seen in patients with moderate renal dysfunction

Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction - From the COMPASS Trial

Literature - Fox KAA, Eikelboom JW, Shestakovska O et al., - J Am Coll Cardiol. 2019;73(18). DOI: 10.1016/j.jacc.2019.02.048

Introduction and methods

Chronic kidney disease (CKD) increases the risk of thromboembolism and bleeding, but anticoagulation therapy also increases bleeding risk in the presence of renal dysfunction [1-4]. Moreover, higher age and the prevalent comorbidities that are associated with vascular disease also negatively impact bleeding risk and adverse vascular outcomes. The extent of renal excretion of non-vitamin K antagonist oral anticoagulants varies, ranging from 25% to 80% of drug being excreted unchanged in the urine [5-7]. Thus, renal dysfunction may alter the risk-benefit balance for antithrombotic combinations.

The COMPASS study demonstrated that rivaroxaban 2.5 mg bd plus aspirin, compared with aspirin alone, reduced CV outcomes and increased major bleeding in patients with stable atherosclerotic vascular disease [8-10]. Rivaroxaban 5 mg twice daily on the other hand, did not reduce CV outcomes and was associated with higher bleeding risk [8].

This analysis assessed the safety and efficacy of low-dose anticoagulation with rivaroxaban plus aspirin (the dual pathway COMPASS regimen), compared with aspirin alone, in patients who are in sinus rhythm but at increased vascular risk, with or without moderate renal dysfunction. Patients in the COMPASS trial had chronic stable CAD and/or peripheral artery disease. 21.111 patients in the COMPASS population had GFR ≥60 mL/min at baseline and 6.275 had GFR <60 mL/min.

Main results

  • The primary efficacy outcome of CV death, MI or stroke, was more frequent in those with renal dysfunction than in those without, and the frequency was inversely related to eGFR.
  • Risk reductions with rivaroxaban plus aspirin were consistent in those with GFR ≥60 mL/min (3.5% vs. 4.5% with aspirin alone, HR: 0.76, 95%CI: 0.64-0.90) and in those with GFR <60 mL/min (6.4% vs. 8.4%, 95%CI: 0.75, 0.60-0.94).
  • Also in those with more severe renal dysfunction (GFR <30 mL/min, n=243), a consistent, but non-significant risk reduction was seen (HR: 0.73, 95%CI: 0.28-1.91).
  • Strokes of any cause were reduced with the dual regime in those with normal renal function (0.9% vs. 1.3%, HR: 0.67, 95%CI: 0.48-0.92) and with GFR <60 mL/min (1.0% vs. 2.3%, HR: 0.42, 95%CI: 0.25-0.70).
  • CV death was lower in the COMPASS regimen group than in those treated with aspirin alone, both in those with GFR ≥60 mL/min (1.3% vs. 1.7%, HR: 0.73, 95%CI: 0.56-0.96) and in those with GFR <60 mL/min (3.5% vs. 3.9%, HR: 0.88, 95%CI: 0.64-1.20).
  • No statistically significant interactions of the treatment effect on various efficacy and safety outcomes and renal function status were seen. When GFR was used on a continuous scale, a consistent benefit of the combination therapy was seen across the GFR range.
  • Major bleeding occurred more often in those randomized to the COMPASS regime than in those on aspirin alone in those with GFR ≥60 mL/min (2.9% vs. 1.6%, HR: 1.81, 95%CI 1.44-2.28) and in those with GFR <60 mL/min (3.9% vs. 2.7%, HR: 1.47, 95%CI: 1.05-2.07).
  • Net clinical benefit with the dual treatment regimen compared with aspirin alone, based on CV death, stroke, MI, fatal bleeding or symptomatic bleeding into critical organ, was consistent in those with GFR ≥60 mL/min (HR: 0.81, 95%CI: 0.69-0.94) and <60 mL/min (HR: 0.79, 95%CI: 0.64-0.98).

Conclusion

This analysis of COMPASS suggests that for both efficacy and safety, the relative treatment effects of the dual-pathway COMPASS regimen, consisting of rivaroxaban 2.5mg bd and aspirin, compared with aspirin alone, are consistent in those with preserved and moderately impaired renal function. A cut-off of GFR of 60 mL/min was used. Relatively few patients included in the COMPASS trial had GFR <30 mL/min, and by design, all had GFR >15 mL/min at baseline.

References

1. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093–100.

2. Vazquez E, Sanchez-Perales C. The HAS-BLED score and renal failure. Chest 2011;139:1248–9. author reply 1249–50.

3. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 2011;58:395–401.

4. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821–30.

5. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the Management of Atrial Fibrillation: an Update of the 2010 ESC Guidelines for the Management of Atrial Fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719–47.

6. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64: e139–228.

7. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962.

8. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377: 1319–30.

9. Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without ASA in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2017;391:205–18.

10. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without ASA in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo controlled trial. Lancet 2017;391:219–29.

Find this article online at JACC

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free